Brokerages predict that Bristol-Myers Squibb Company (NYSE:BMY) will report sales of $5.29 billion for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Bristol-Myers Squibb’s earnings, with the lowest sales estimate coming in at $5.20 billion and the highest estimate coming in at $5.43 billion. Bristol-Myers Squibb reported sales of $5.24 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 1%. The business is scheduled to issue its next earnings report on Thursday, January 25th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full year sales of $5.29 billion for the current fiscal year, with estimates ranging from $20.44 billion to $20.77 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $21.25 billion per share, with estimates ranging from $20.82 billion to $21.78 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the company earned $0.77 earnings per share.

Several research analysts have commented on the stock. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Goldman Sachs Group reissued a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Cowen restated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Jefferies Group restated a “buy” rating and set a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $64.93.

Bristol-Myers Squibb (NYSE BMY) opened at $63.19 on Friday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a market cap of $103,320.00, a price-to-earnings ratio of 21.12, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.23% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Blue Chip Partners Inc. raised its stake in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its stake in Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares in the last quarter. Keel Point LLC boosted its stake in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 18 shares in the last quarter. Shayne & CO. LLC boosted its stake in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 24 shares during the period. Finally, Chilton Investment Co. LLC raised its holdings in Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 26 shares in the last quarter. 69.69% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/bristol-myers-squibb-company-bmy-expected-to-announce-quarterly-sales-of-5-29-billion.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.